

Katerina Bakunina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10183339/publications.pdf>

Version: 2024-02-01

7
papers

274
citations

1684188
5
h-index

1720034
7
g-index

7
all docs

7
docs citations

7
times ranked

406
citing authors

#	ARTICLE	IF	CITATIONS
1	Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology</i> , The, 2019, 20, 216-228.	10.7	163
2	Rituximab in primary central nervous system lymphoma – A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2019, 37, 548-557.	1.7	54
3	Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial. <i>Haematologica</i> , 2020, 105, 2805-2812.	3.5	30
4	Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial. <i>Neuro-Oncology</i> , 2021, 23, 1315-1326.	1.2	9
5	MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma. <i>Journal of Neuro-Oncology</i> , 2021, 152, 357-362.	2.9	8
6	Extent of radiological response does not reflect survival in primary central nervous system lymphoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab007.	0.7	7
7	The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed. <i>Cancer Medicine</i> , 2022, 11, 630-640.	2.8	3